Table S1. Univariate and multivariable analyses of local progression-free survival

| Variable                                      | Univariate analysis | Multivariate analysis |
|-----------------------------------------------|---------------------|-----------------------|
|                                               | HR (95% CI)         | p-value               | HR (95% CI)         | p-value               |
| Sex (male vs. female)                         | 1.90 (0.72–5.04)    | 0.20                  |                       |                       |
| Age (≥65 vs. <65 yr)                          | 1.22 (0.48–3.10)    | 0.68                  |                       |                       |
| KPS (90–100 vs. 70–80)                        | 0.75 (0.17–3.29)    | 0.71                  |                       |                       |
| Disease extent (BRPC vs. LAPC)                | 0.98 (0.39–2.47)    | 0.97                  |                       |                       |
| Tumor location (head vs. other)               | 1.67 (0.66–4.24)    | 0.28                  |                       |                       |
| Tumor size (≥3.6 vs. <3.6 cm)                 | 0.63 (0.26–1.57)    | 0.32                  |                       |                       |
| Baseline CA19-9 (>148 vs. ≤148 U/mL)         | 3.93 (0.79–19.53)   | 0.095                 |                       |                       |
| Chemo duration (>4 vs. ≤4 mo)                 | 1.01 (0.39–2.57)    | 0.99                  |                       |                       |
| PNI (absent vs. present)                      | 0.53 (0.18–1.60)    | 0.26                  |                       |                       |
| LVI (absent vs. present)                      | 0.49 (0.20–1.25)    | 0.14                  |                       |                       |
| Adjuvant/maintenance chemotherapy (yes vs. no)| 0.41 (0.14–1.21)    | 0.11                  |                       |                       |
| KRA$\upalpha$ (mutant vs. wild type)          | 23.30 (0.019–28,351.67) | 0.39             |                       |                       |
| TP53 (mutant vs. wild type)                   | 0.79 (0.32–1.95)    | 0.61                  |                       |                       |
| NOTCH1/2 (mutant vs. wild type)               | 1.87 (0.65–5.33)    | 0.24                  |                       |                       |
| CDKN2A (mutant vs. wild type)                 | 0.99 (0.33–2.99)    | 0.99                  |                       |                       |

KPS, Karnofsky Performance Score; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; CA19-9, cancer antigen 19-9; PNI, perineural invasion; LVI, lymphovascular invasion; HR, hazard ratio; CI, confidence interval.